ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Autoinflammatory diseases"

  • Abstract Number: L03 • ACR Convergence 2023

    Efficacy and Safety of Targeted Therapies in VEXAS Syndrome: Retrospective Study from the French VEXAS Group

    Jerome Hadjadj1, Yann Nguyen1, Dalila Mouloudji1, Rim Bourguiba1, Mael Heiblig2, Aloui Hassina1, Valentin Lacombe3, Samuel Ardois4, Corrado Campochiaro5, Alexandre Maria6, Thibault Comont7, Estibaliz Lazaro8, Francois Lifermann9, Guillaume Le Guenno10, Herve Lobbes10, Roderau Outh11, Julien Campagne12, Cyrille Coustal6, Alice Garnier13, Yvan Jamilloux2, Aurore Meyer14, Noemie Abisror15, Olivier Kosmider1, Vincent Jachiet1, Olivier FAIN16, Benjamin Terrier17, Arsene Mekinian1 and Sophie Georgin-Lavialle18, 1APHP, Paris, France, 2Lyon Hospital, Lyon, France, 3Angers Hospital, Angers, France, 4Rennes Hospital, Rennes, France, 5San Raffaele Scientific Institute, Milan, Italy, 6Montpellier Hospital, Montpellier, France, 7Oncopole Toulouse, Toulouse, France, 8Bordeaux Hospital University, Pessac, France, 9Dax Hospital, Dax, France, 10Clermont Hospital, Clermont Ferrand, France, 11Perpignan Hospital, Perpignan, France, 12Hpital Robert Schuman, Metz, France, 13Nantes Hospital, Nantes, France, 14Strasbourg Hospital, Strasbourg, France, 15Internal Medicine Saint Antoine Hospital, Paris, France, 16Hopital Saint Antoine APHP, Paris, France, 17Cochin Hospital, Paris, France, 18AP-HP, Tenon hospital, Paris, France

    Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a monogenic disease of adults due to acquired somatic mutations of the UBA1 gene. Patients…
  • Abstract Number: 0039 • ACR Convergence 2023

    Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis

    Mariana Correia Marques1, Danielle Rubin1, Emily Shuldiner2, Mallika Datta1, Elizabeth Schmitz1, Alexei Grom3, Dirk Foell4, Marco Gattorno5, John Bohnsack6, Rae Yeung7, Sampath Prahalad8, Elizabeth Mellins9, Jordi Anton Lopez10, Claudio Len11, Sheila Oliveira12, Patricia Woo13, Seza Ozen14, INCHARGE Consortium1, Zuoming Deng15 and Michael Ombrello1, 1National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Department of Biology, Stanford University, Stanford, CA, 3Division of Rheumatology, Cincinnati Children`s Hospital, Cincinnati, OH, 4University Hospital Münster, Münster, Germany, 5UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 6University of Utah, Salt Lake City, UT, 7The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 8Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, 9Stanford University, Stanford, CA, 10Pediatric Rheumatology Department, Hospital Sant Joan e Deu, Barcelona University, Barcelona, Spain, 11São Paulo Federal University, São Paulo, Brazil, 12Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 13University College London, London, United Kingdom, 14Hacettepe University Medical Faculty, Ankara, Turkey, 15National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a complex inflammatory condition of childhood. It can be complicated by macrophage activation syndrome (MAS), a secondary form…
  • Abstract Number: 0278 • ACR Convergence 2023

    NOD2 Genotyping Landscape in Yao Syndrome

    Hafsa Nomani1, Ashmia Saif2, Frank Hwang1 and Qingping Yao1, 1Stony Brook University, Stony Brook, NY, 2Stony Brook University Hospital, Syosset, NY

    Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. This study…
  • Abstract Number: 1146 • ACR Convergence 2023

    Gene X Environment Paradigm: Exemplified by Selected Cases of Autoinflammatory Diseases

    Qingping Yao and Peter Gorevic, Stony Brook University, Stony Brook, NY

    Background/Purpose: The current scientific opinion holds that gene and environment (G X E) interactions contribute to certain human diseases. Systemic autoinflammatory diseases (SAIDs) are usually…
  • Abstract Number: 1929 • ACR Convergence 2023

    Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience

    Zeynep Toker Dincer1, Sejla Karup2, Erkin Yilmaz1, Osman Corbali1 and Serdal Ugurlu1, 1Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of…
  • Abstract Number: PP11 • ACR Convergence 2023

    We Suffered For Decades, But Then She Was Born

    Ian Stedman1 and Barbara Stedman2, 1Canadian Autoinflammatory Network, Vaughan, ON, Canada, 2Canadian Autoinflammatory Network, Turkey Point, ON, Canada

    Background/Purpose: I was born in 1981; my mother in 1949; and my grandmother in 1926. Our story runs at least four generations deep, that we…
  • Abstract Number: 0064 • ACR Convergence 2023

    Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

    Vincent ricchiuti1, Michael Nappi2, Kelly Chun2, Ajay Grover1 and Rubio Punzalan2, 1Labcorp, Dublin, OH, 2Labcorp, Calabasas, CA

    Background/Purpose: The discovery and characterization of the dense fine speckled (DFS, ICAP AC-2) nuclear pattern of antinuclear autoantibodies (ANA) detected in HEp-2 cells by indirect…
  • Abstract Number: 0306 • ACR Convergence 2023

    Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy

    Akanksha Sharma1, shiri keret2, Raisa Lomanto Silva3, Tanya Chandra4, Joel Levin5, Siamak Moghadam-Kia3, Chester V. Oddis6 and Rohit Aggarwal6, 1UPMC Mercy Hospital, Pittsburgh, PA, 2Bnai Zion, Atlit, Israel, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Georgetown University Hospital, Washington, DC, 5University of Pittsburgh, Katz Graduate School, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM, myositis) are a systemic autoimmune disease leading to debilitating muscle weakness and significant limitations in daily activities. Physical activity monitor…
  • Abstract Number: 1148 • ACR Convergence 2023

    A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome

    Ashmia Saif1, Hafsa Nomani2, Frank Hwang2, Jie Yang2 and Qingping Yao2, 1Stony Brook University Hospital, Syosset, NY, 2Stony Brook University, Stony Brook, NY

    Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
  • Abstract Number: 1932 • ACR Convergence 2023

    The Association Between Initial Ferritin and Complications from Adults Onset Stills Disease and Intensive Care Unit Admission

    Olivia Yang1, Caroline Bui1, Scott Kubomoto1, Napatkamon Ayutyanont1, Kimberly Vickery1 and Kumar Venkat2, 1Riverside Community Hospital, Riverside, CA, 2Retired, Irvine, CA

    Background/Purpose: Adult Onset Still's Disease (AOSD) is an autoinflammatory disease characterized by quotidian fever, arthralgia, and a salmon colored rash. Due to its rarity, there…
  • Abstract Number: 0039.5 • ACR Convergence 2023

    Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases

    Haruka Takahashi1, Hiroaki Hatano2, Masahiro Nakano3, Haruka Tsuchiya4, Mineto Ota4, Tomohisa Okamura5, Keishi Fujio4 and Kazuyoshi Ishigaki6, 1Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences and Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 3Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 6RIKEN, Tokyo, Japan

    Background/Purpose: Abnormal cytokine regulation is the fundamental pathology of immune-mediated diseases (IMDs). Clinical transcriptome data has a potential to monitor real-time cytokine pathway activities of…
  • Abstract Number: 0539 • ACR Convergence 2023

    Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis

    Maxime Dougados1, David Bulbin2, Heather Jones3, Tianming Gao4, Anna Shmagel5, Thomas Poznanski6, Abhijeet Danve7 and Karl Gaffney8, 1Université de Paris, Paris, France, 2Geisinger Health System, Danville, PA, 3AbbVie, Inc., Mettawa, IL, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Long Grove, IL, 6AbbVie, Inc., Plainfield, IL, 7Yale University, New Haven, CT, 8Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom

    Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…
  • Abstract Number: 1240 • ACR Convergence 2023

    Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash

    Ilaria Maccora1, Patricia Vega-Fernandez2, Kimberly Risma3 and Grant Schulert4, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital, Medical Centre, Cincinnati, OH, 3Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…
  • Abstract Number: 1936 • ACR Convergence 2023

    Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry

    Gerd Horneff1, Norbert Blank2, Jasmin B. Kuemmerle-Deschner3, Joerg Henes4, Birgit Kortus-Goetze5, Prasad T. Oommen6, Anne Pankow7, Tobias Krickau8, Catharina Schuetz9, Ivan Foeldvari10, Juergen Rech11, Frank Weller-Heinemann12, Ales Janda13, Markus Hufnagel14, Florian M. Meier15, Frank Dressler16, Michael Borte17, Ioana Andreica18, Peter Wasiliew19, Michael Fiene20, Daniel Windschall21, Martin Krusche22, Tania Kuempfel23, Julia Weber-Arden24 and Tilmann Kallinich25, 1Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, 2University Hospital Heidelberg, Heidelberg, Germany, 3med.uni-tuebingen, Tübingen, Germany, 4University Hospital Tuebingen, Tuebingen, Germany, 5Department of Internal Medicine, Division of Nephrology,University Hospital of Giessen and Marburg, Marburg, Germany, 6Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health,Medical Faculty Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 7Department of Rheumatology and Clinical Immunology,Charité-Universitätsmedizin Berlin, Berlin, Germany, 8Pediatrics, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen, Germany, 9Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus,Technische Universität Dresden, Dresden, Germany, 10Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 11University Clinic Erlangen, Erlangen, Germany, 12Division of Pediatric Rheumatology, Prof. Hess Children's Hospital, Bremen, Bremen, Germany, 13Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany, 14Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, 15Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, Frankfurt am Main, Germany, 16Department of Paediatric Pneumology, Allergology and Neonatology, Children's Hospital, Hannover Medical School, Hannover, Germany, 17Hospital for Children & Adolescents, St. Georg Hospital, Leipzig, Germany, 18Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 19Division of Pediatric Rheumatology and autoinflammation reference center Tuebingen, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 20Rheumatology Center Greifswald, Greifswald, Germany, 21Clinic of Paediatric and Adolescent Rheumatology, St. Josef-Stift Sendenhorst, Northwest German Center for Rheumatology, Sendenhorst, Germany, 22UKE, Hamburg, Germany, 23Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universität München, Muenchen, Germany, 24Novartis Innovative Medicines, Nuernberg, Germany, 25Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Nuremberg, Germany

    Background/Purpose: Pediatric patients with autoinflammatory diseases (AID) on Canakinumab (CAN) therapy have been affected by the coronavirus pandemic including SARS-CoV-2 infection, SARS-CoV-2 vaccination, and AID…
  • Abstract Number: 0087 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients

    Kathryne Marks1, Anvita Singaraju2, Runci Wang3, Ifeoluwakiisi Adejoorin1, Miriam Fein2, Michael Postow4, Karmela Kim Chan2, Anne Bass5, Laura Donlin2 and Deepak Rao1, 1Brigham and Women's Hospital, Boston, MA, 2Hospital for Special Surgery, New York, NY, 3Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China, 4Memorial Sloan Kettering Cancer Center, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Immune checkpoint inhibitor (ICI) therapies used to treat cancer can induce immune related Adverse events (irAEs) such as ICI-induced arthritis (ICI-arthritis). We have previously…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology